JAZZ
Jazz Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.79 / 10
Netural
Analyst coverage shows two Buy recommendations (Barclays, Piper Sandler) with mixed track records; Piper Sandler’s past success is 66.7%, Barclays’ is negative. Fund‑flow sentiment is strong (7.88/10) with positive inflows across all investor sizes, supporting a bullish bias.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-19
InstitutionPiper Sandler
Times predicted3
Historical Win Rate66.7%
What is the market sentiment for JAZZ?
- JAZZ holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.79/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
